News Releases
Approval for Epadel S900, EPA Product with New Dose
A Therapeutic Agent for the Treatment of Hyperlipidemia and Arteriosclerosis Obliterans
(Tokyo, March 15, 2004) - Mochida Pharmaceutical Co., Ltd. (President: Naoyuki Mochida) announces that it has approval to manufacture Epadel S900 (ethyl icosapentate, soft capsule), a therapeutic agent for the treatment of hyperlipidemia and arteriosclerosis obliterans.
Mochida launched the world's first high-purity ethyl icosapentate (EPA) product Epadel Capsules in June 1990, followed by new formulation Epadel S300 and Epadel S600 in smaller spherical capsules (4 mm in diameter) in separate packages, in January 1999.
The newly approved Epadel S900 features 900 mg EPA per pack, and will join the existing lineup including Epadel S300 and Epadel S600. This product is expected to be patients with hyperlipidemia, particularly those with abnormal triglyceride levels who need as much as 2,700 mg/day of EPA.
EPA is a polyunsaturated fatty acid found in fish oil, with anti-atherosclerotic effects first during epidemiological investigations in Greenland. Collaboration between Nippon Suisan and Mochida resulted in Epadel, the world's first EPA pharmaceutical.